Larry H Danziger
Overview
Explore the profile of Larry H Danziger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
836
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Drwiega E, Johnson S, Danziger L, Skinner A
Infect Control Hosp Epidemiol
. 2024 Oct;
:1-7.
PMID: 39387193
Background: Reducing rehospitalization has been a primary focus of hospitals and payors. Recurrence of infection (CDI) is common and often results in rehospitalization. Factors that influence rehospitalization for CDI are...
2.
Hunt A, Danziger L, Johnson S, Skinner A
Open Forum Infect Dis
. 2024 Apr;
11(4):ofae153.
PMID: 38665169
Vancomycin and fidaxomicin taper regimens were the most common treatment strategies employed but nearly half of patients (40/83) referred to our infection (CDI) clinic did not require further treatment. The...
3.
Drwiega E, Danziger L, Burgos R, Michienzi S
J Pharm Pract
. 2023 Apr;
37(3):741-752.
PMID: 37018738
Mosquito-borne diseases are a public health concern. Pharmacists are often a patient's first stop for health information and may be asked questions regarding transmission, symptoms, and treatment of mosquito borne...
4.
Drwiega E, Griffith N, Danziger L
Expert Opin Drug Metab Toxicol
. 2022 May;
18(4):245-259.
PMID: 35594628
Introduction: Cefiderocol is a siderophore cephalosporin antibiotic and first of its kind approved by the Food and Drug Administration for the treatment of complicated urinary tract infections (cUTI) and hospital-acquired...
5.
Skinner A, Tan X, Sirbu B, Danziger L, Gerding D, Johnson S
Clin Infect Dis
. 2021 Mar;
73(6):1107-1109.
PMID: 33714998
We treated 46 patients with multiple recurrent Clostridioides difficile infections (mrCDI) using a tapered-pulsed (T-P) fidaxomicin regimen, the majority of whom failed prior T-P vancomycin treatment. Sustained clinical response rates...
6.
Schriever C, Danziger L
Clin Infect Dis
. 2019 Oct;
71(1):87-88.
PMID: 31584630
No abstract available.
7.
Meyer K, Deraedt M, Harrington A, Danziger L, Wenzler E
Int J Antimicrob Agents
. 2019 Apr;
54(2):197-201.
PMID: 31034937
Objective: The optimal therapy for serious enterococcal infections, especially vancomycin-resistant enterococci (VRE), remains unclear, although combination therapy is often recommended. Oritavancin has demonstrated in-vitro activity against VRE, but data evaluating...
8.
Pharmacokinetic evaluation of meropenem and vaborbactam for the treatment of urinary tract infection
Burgos R, Biagi M, Rodvold K, Danziger L
Expert Opin Drug Metab Toxicol
. 2018 Aug;
14(10):1007-1021.
PMID: 30106599
Meropenem/vaborbactam (M/V) represents the first carbapenem and β-lactamase inhibitor combination approved for treatment of complicated urinary tract infections (cUTIs), including pyelonephritis. Vaborbactam is a novel boronic acid, β-lactamase inhibitor with...
9.
Wenzler E, Bleasdale S, Sikka M, Bunnell K, Finnemeyer M, Rosenkranz S, et al.
Antimicrob Agents Chemother
. 2018 Jun;
62(8).
PMID: 29891606
The pharmacokinetics (PK), safety, and tolerability of two repeated dosing regimens of oral fosfomycin tromethamine were evaluated in 18 healthy adult subjects. Subjects received 3 g every other day (QOD)...
10.
Bunnell K, Wenzler E, Harrington A, Danziger L
Diagn Microbiol Infect Dis
. 2018 Feb;
90(4):335-336.
PMID: 29395714
Breakpoint changes may impact cephalosporin susceptibility rates in uncomplicated urinary tract infections (uUTIs). Applying the ≤16-mg/L breakpoint to urine cultures from adult women in an academic health system resulted in...